A Phase 3 clinical trial for a new flu treatment has completed enrollment of 2,021 patients. Along with the drug company MediVector, Inc., the Department of Defense sponsored the trial as part of its Joint Program Executive Office for Chemical and Biological Defense. The investigational drug used in the clinical trials is favipiravir. It works by selectively disrupting the ribonucleic acid (RNA) viral replication process within infected cells to stop the infection cycle. Patients from North and South America, Europe, Australia, New Zealand and South Africa were enrolled in the trial. Favipiravir is already approved in Japan to treat drug-resistant and pandemic influenza.
Thank you to our patients who enrolled in our studies for favipiravir this year and last year!
